Aptargroup, Inc. · NYSE:ATR
Aptargroup — Q2 2026 Earnings Presentation
28 slides from Aptargroup's earnings presentation, Jul 31, 2026
Slide 1: Q2 2026 Results
July 31, 2026 Q2 2026 Results Stephan B. Tanda, Aptar President and CEO Vanessa Kanu, Executive Vice President and CFO Gael Touya, President of Aptar Pharma & Aptar President and CEO Designate
Slide 2: Forward Looking Statements & Non-GAAP Financial Measures
Forward Looking Statements & Non-GAAP Financial Measures This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based
Slide 3: Q2 2026 Financial Highlights
Q2 2026 Financial Highlights Second Quarter 2026 Highlights: 6% Q2 Reported Sales Growth 1% Q2 Core Sales Growth* • Delivered revenue growth across all three segments during the quarter • Aptar Pharma continued to lead the way, driven by double-digit growth in consumer healthcare, and high $1.36 $1.
Slide 4: Recent News, Products and Technology Highlights
Recent News, Products and Technology Highlights Pharma Beauty Closures First commercial launch of Fragrance pump for a Tab Top Closure Closure with Foundational U.S. patent application Launched integrated system- SimpliSqueezeTM NeoDropper, our auto-loading, Middle East fragrance for Heinz dipping f
Slide 5: Recent Recognitions
Recent Recognitions Our award-winning commitment to sustainability is a competitive advantage CDP TIME TIME CDP EcoVadis Forbes Newsweek ISS ESG USA Today Recognized as a One of One of the Climate A Sustainability Rating One of the In the Top 100 Achieved One of World’s Most World’s Top Prime Suppli
Slide 6: Second Quarter 2026 Reported Results
Second Quarter 2026 Reported Results Q2 Reported Sales Q2 Reported EPS $1,200 (in millions $) $1.80 $1.67 $1,027 -19% $966 6% $1.60 $1,000 $1.36 $1.40 $800 $1.20 $1.00 $600 $0.80 $400 $0.60 $0.40 $200 $0.20 $- $- Q2 2025 Q2 2026 Q2 2025 Q2 2026 +2% 20.0% 23.5% +1% Currency Effects Q2 2025 Q2 2026 Co
Slide 7: Second Quarter 2026 Adj. EPS and Adj. EBITDA
Second Quarter 2026 Adj. EPS and Adj. EBITDA Q2 Adjusted EPS * Q2 Adjusted EBITDA* (in millions $) $1.80 $1.68 $280 $1.60 -15% $1.42 $240 $218 -3% $213 $1.40 $200 $1.20 $1.00 $160 $0.80 $120 $0.60 $80 $0.40 $40 $0.20 $- $- Q2 2025 Q2 2026 Q2 2025 Q2 2026 20.0% 23.7% Q2 2025 Q2 2026 Effective Tax Eff
Slide 8: Pharma Second Quarter 2026 Results
Pharma Second Quarter 2026 Results * Q2 2026 Core Sales* by Market • Prescription core sales decreased 7% • Consumer Healthcare core sales increased 15% • Injectables core sales increased 9% • Active Material Science core sales decreased 2% YTD 2026 Percentage of Sales by Market 10% Proprietary Drug
Slide 9: Beauty Second Quarter 2026 Results
Beauty Second Quarter 2026 Results Q2 2026 Core Sales* by Market * • Fragrance, Facial Skincare and Color Cosmetics (F&F) core sales increased 2% • Personal Care core sales were flat YTD 2026 Percentage of Sales by Market 4% Fragrance F&F** and 36% Facial skincare Personal Care 60% Aptar Beauty’s Ad
Slide 10: Closures Second Quarter 2026 Results
Closures Second Quarter 2026 Results * Q2 2026 Core Sales* by Market • Food core sales decreased 1% • Beverage core sales increased 14% YTD 2026 Percentage of Sales by Market 7% 16% Food Beverage 48% Personal Care 29% Other* Aptar Closures’ Adj. EBITDA Margin* *Other includes Beauty and Home Care ma
Slide 11: Year-to-Date 2026 Reported Results
Year-to-Date 2026 Reported Results YTD Reported Sales YTD Reported EPS (in millions $) $2,500 $3.50 $2,009 $3.00 $2.83 -12% $2,000 $1,853 8% $2.48 $2.50 $1,500 $2.00 $1.50 $1,000 $1.00 $500 $0.50 $- $- YTD 2025 YTD 2026 YTD 2025 YTD 2026 +4% 22.5% 23.0% +1% Currency Effects YTD 2025 YTD 2026 Core Sa
Slide 12: Year-to-Date 2026 Adj. EPS and Adj. EBITDA
Year-to-Date 2026 Adj. EPS and Adj. EBITDA YTD Adjusted EPS * YTD Adjusted EBITDA * (in millions $) $3.50 $500 $3.00 $2.98 -12% $402 Flat $401 $2.61 $400 $2.50 $2.00 $300 $1.50 $200 $1.00 $100 $0.50 $- $- YTD 2025 YTD 2026 YTD 2025 YTD 2026 22.6% 23.2% YTD 2025 YTD 2026 Effective Tax Effective Tax R
Slide 13: Outlook
Outlook Outlook Highlights Earnings Per Share • In alignment with Gael Touya, who will assume the role of CEO $2.00 $1.92 on September 1, we enter the third quarter with confidence $1.80 $1.61 • We expect solid growth across all three segments $1.60 $1.45 – $1.53 $1.40 • In Pharma, injectables and c
Slide 14: Key Highlights for Q3 / FY2026
Key Highlights for Q3 / FY2026 Quarterly (Expected) Effective Tax Rate 22.5% to 24.5% for Q3 2026 Prior year Q3 comparable adjusted effective tax rate = 20.4% Currency Guidance (Euro) 1.14 for Q3 2026 Assuming a Euro to USD Exchange Rate Full Year (Expected) CapEx Range for Full Year 2026 $260 to $2
Slide 15: Appendix
Aptar.4 Appendix
Slide 16: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 16
Slide 17: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 17
Slide 18: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands Except Per Share Data) 18
Slide 19: Reconciliation of Adjusted Earnings Per Diluted Share
Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited) ($ In Thousands, Except Per Share Data) 19
Slide 20: Reconciliation of Reported to Core Sales Growth by Market
Reconciliation of Reported to Core Sales Growth by Market (Rounded to the nearest whole percent) 20
Slide 21: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 21
Slide 22: Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)
Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited) ($ In Thousands) 22
Slide 23: Reconciliation of Adjusted EBIT After Taxes to Net Income
Reconciliation of Adjusted EBIT After Taxes to Net Income (Unaudited) ($ In Thousands) 23
Slide 24: Reconciliation of Capital to Stockholders' Equity
Reconciliation of Capital to Stockholders’ Equity (Unaudited) ($ In Thousands) 24
Slide 25: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 25
Slide 26: Reconciliation of Free Cash Flow to Net Cash Provided by Operations
Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited) ($ In Thousands) 26
Slide 27: Supplemental Information
Supplemental Information 27
Slide 28: Follow us on:
265 Exchange Drive Suite 301 Crystal Lake, IL 60014 +1-815-477-0424 Aptar.com Follow us on: 28